A Comprehensive Study Of Non-Alcoholic Fatty Liver Disorder Literature Review

The prevalence of non-alcoholic fatty liver disorder (NAFLD) spans approximately 25% globally. The rate of occurrence is on the rise due to escalating rates of obesity, type 2 diabetes, and the metabolic syndrome. It is anticipated that NAFLD will emerge as the primary cause of cirrhosis necessitating liver transplants in the upcoming decade. Nevertheless, cardiovascular ailments remain the leading cause of mortality, and only a small fraction of individuals will develop fibrosis and liver associated complications. Hence, it is crucial to identify patients with progressive disease using non-invasive fibrosis markers, which encompass serology based assess-ents (e.g., NAFLD Fibrosis Score and ELF test) and imaging techniques (e.g., transient elastography). This approach aims to pinpoint suitable candidates for refer-al to secondary care for further evaluations like liver biopsy and expert assistance. Adjustments in lifestyle and weight reduction continue to be the foundation of treatment, yet we are poised to embark on a new phase of hopeful pharmacological therapies for NASH and fibrosis.Keywords: Non-Alcoholic Fatty Liver Disease, Fibrosis, Diagnosis, Management, Liver Disease